Serum galactomannan and (1→3)-β-D-glucan assays for patients with multiple myeloma and Waldenstrom's macroglobulinemia

5Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We assessed the performance of galactomannan and (1→3)-β-D-glucan in 29 serum samples from patients with multiple myeloma and Waldenstrom's macroglobulinemia without invasive fungal disease to address issues of false positivity and uninterpretable results previously reported among patients with these conditions. Galactomannan and (1→3)-β-D-glucan assays were not falsely elevated in any patient. (1→3)-β-D-glucan assay results were uninterpretable in 24% of patients. Patients with IgG levels of>2,000 mg/dl had higher odds of uninterpretable (1→3)-β-D-glucan results. Copyright © 2012, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Issa, N. C., Koo, S., Lynch, R. C., Gay, C., Hammond, S. P., Baden, L. R., … Marty, F. M. (2012). Serum galactomannan and (1→3)-β-D-glucan assays for patients with multiple myeloma and Waldenstrom’s macroglobulinemia. Journal of Clinical Microbiology, 50(3), 1054–1056. https://doi.org/10.1128/JCM.06295-11

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free